Beta-Blockers for Migraine Prevention
Beta-blockers were among the first drugs shown to prevent migraine and remain a mainstay of oral prophylaxis. Propranolol and metoprolol have the strongest evidence (AAN/AHS Level A). They are particularly useful when migraine coexists with hypertension, anxiety, or essential tremor. Not all beta-blockers are equally effective — those with intrinsic sympathomimetic activity (ISA) are not effective for migraine.
Bottom Line
- Propranolol (80-240 mg/day) and metoprolol (100-200 mg/day) have Level A evidence
- Timolol is the only beta-blocker with an FDA indication for migraine prevention (rarely used in practice)
- Reduce migraine frequency by ~40-50% in responders; NNT ~3-4
- Best candidates: Comorbid hypertension, anxiety, essential tremor, tachycardia; pregnancy (propranolol); cost-sensitive patients
- Avoid in: Asthma, bradycardia, depression, diabetes (masks hypoglycemia), Raynaud’s, athletes requiring peak performance
- Beta-blockers with ISA (pindolol, acebutolol) are NOT effective for migraine
- Cost advantage: Generic propranolol costs ~$4-10/month vs $600+/month for CGRP therapies
Which Beta-Blockers Work?
| Agent | Evidence Level | Dose Range | Selectivity | Notes |
|---|---|---|---|---|
| Propranolol | Level A | 80-240 mg/day (divided BID or LA once daily) | Non-selective | Most studied beta-blocker in migraine; long-acting formulation available |
| Metoprolol | Level A | 100-200 mg/day (ER once daily) | Beta-1 selective | Preferred over propranolol in mild asthma/COPD due to selectivity |
| Timolol | Level A | 10-30 mg/day (divided BID) | Non-selective | FDA-approved for migraine; rarely prescribed (less familiar) |
| Atenolol | Level B | 50-200 mg/day | Beta-1 selective | Once daily dosing; less CNS penetration (fewer sleep/mood effects) |
| Nadolol | Level B | 40-160 mg/day | Non-selective | Long half-life (once daily); good option when propranolol causes fatigue |
| Nebivolol | Level C | 5-10 mg/day | Beta-1 selective | Limited migraine data; NO-mediated vasodilation may be theoretically beneficial |
🔴 Beta-Blockers NOT Effective for Migraine
- Pindolol — has ISA (partial agonist activity); no migraine benefit
- Acebutolol — has ISA; no migraine benefit
- Labetalol — combined alpha/beta blocker; not studied for migraine and not recommended
- The mechanism of beta-blocker efficacy in migraine is not fully understood but is thought to involve central serotonergic effects and inhibition of cortical spreading depression — properties that ISA-containing agents lack
Key Trial Data
Propranolol
- Multiple RCTs since the 1970s consistently show ~40-50% reduction in migraine frequency
- Cochrane Review (Linde 2004): Pooled analysis of 26 trials confirmed propranolol is superior to placebo for migraine prevention with NNT of approximately 3-4
- Comparable to topiramate: The TOPMAT-MIG-301 trial showed propranolol 160 mg/day and topiramate 100 mg/day had similar efficacy in episodic migraine (~44% vs 45% responder rates), but propranolol had fewer cognitive side effects
Metoprolol
- Steiner et al. (1988): Metoprolol 200 mg/day reduced migraine frequency by 36% vs placebo
- Comparable to propranolol in direct comparison trials with similar responder rates
- Advantage: beta-1 selectivity makes it safer in patients with mild reactive airway disease
Positioning: Beta-Blockers vs Newer Therapies
With the advent of CGRP-targeted therapies, where do beta-blockers fit in modern migraine management?
| Factor | Beta-Blockers | CGRP mAbs/Gepants |
|---|---|---|
| Efficacy | ~40-50% responder rate | ~50-60% responder rate |
| Tolerability | Fatigue, exercise intolerance, bradycardia | Constipation (erenumab), injection site reactions |
| Cost (monthly) | $4-15 (generic) | $600-700 (without insurance) |
| Insurance access | No prior authorization | Often requires 2+ oral preventive failures |
| Comorbidity benefit | HTN, anxiety, tremor, tachycardia | None (migraine-specific) |
| Pregnancy | Propranolol: reasonable option (Category C) | Not recommended (long washout) |
The HER-MES trial compared erenumab to topiramate (not beta-blockers), but provides context: erenumab had dramatically better tolerability (10.6% vs 38.9% discontinuation). Beta-blockers generally fall between these — better tolerated than topiramate, but with more side effects than CGRP therapies.
When to Choose a Beta-Blocker Over CGRP Therapy
- Cost-sensitive patients: Beta-blockers cost ~1% of CGRP therapy price
- Comorbid conditions: Hypertension, anxiety, essential tremor, tachycardia — treat two conditions with one drug
- Pregnancy planning: Propranolol has more safety data than any CGRP therapy
- Insurance requirements: Most insurers require trial of oral preventives before approving CGRP therapy
- Patient preference: Some patients prefer a daily pill over monthly injection
- First-line for mild-moderate episodic migraine: Reasonable to start here if no contraindications
Practical Prescribing
Starting and Titrating
- Propranolol: Start 40 mg BID (or 80 mg LA once daily). Titrate every 2-4 weeks. Target 160-240 mg/day. Max benefit typically at 120-240 mg.
- Metoprolol ER: Start 50 mg once daily. Titrate to 100-200 mg once daily over 2-4 weeks.
- Onset of benefit: 4-8 weeks at therapeutic dose; assess after 2-3 months at target dose
- Do not stop abruptly — taper over 1-2 weeks to avoid rebound tachycardia and hypertension
- Check resting heart rate and blood pressure at baseline and follow-up
Combination Therapy
Beta-blockers can be combined with other preventives when monotherapy provides partial benefit:
| Combination | Rationale | Considerations |
|---|---|---|
| Beta-blocker + Amitriptyline | Classic combination; complementary mechanisms; additive efficacy in some studies | Monitor for excessive bradycardia; both can cause fatigue |
| Beta-blocker + CGRP mAb | Different mechanisms; can continue beta-blocker when starting mAb | May be able to taper beta-blocker once mAb effect established |
| Beta-blocker + Topiramate | Different mechanisms; both effective | Topiramate can cause paresthesias and cognitive issues; additive fatigue |
| Beta-blocker + OnabotulinumtoxinA | Different mechanisms; reasonable for refractory chronic migraine | Often used during Botox initiation while waiting for full effect |
Combination Therapy Pearls
- Beta-blocker + low-dose amitriptyline (10-25 mg) is a time-tested combination, especially for patients with insomnia or tension-type overlap
- When starting a CGRP mAb, continue the beta-blocker initially — don’t stop abruptly. Reassess after 3 months and consider tapering if excellent response
- Avoid combining two medications with significant fatigue profiles unless necessary
Drug Interactions
🔴 Important Drug Interactions
- Propranolol + Rizatriptan: Propranolol inhibits MAO-A, which metabolizes rizatriptan. Reduce rizatriptan to 5 mg (max 15 mg/24h) when used with propranolol.
- Beta-blockers + Verapamil/Diltiazem: Additive AV nodal suppression; risk of severe bradycardia and heart block. Use with caution.
- Beta-blockers + Clonidine: Risk of rebound hypertension if clonidine stopped; taper clonidine before stopping beta-blocker.
- Propranolol + CYP1A2 inhibitors (fluvoxamine, ciprofloxacin): Increased propranolol levels; may need dose reduction.
- Non-selective beta-blockers + Epinephrine: Risk of severe hypertension and reflex bradycardia. Avoid in patients receiving allergy immunotherapy or at risk of anaphylaxis.
Special Populations
Pregnancy
Propranolol is one of the few migraine preventives with reasonable pregnancy safety data:
- Category C (risk cannot be ruled out), but extensive human experience
- Generally considered acceptable in pregnancy when preventive therapy is needed
- Risks: Intrauterine growth restriction (IUGR), neonatal bradycardia, hypoglycemia — more concerning with high doses and third-trimester use
- Practical approach: Use lowest effective dose; monitor fetal growth; alert pediatricians to observe neonate for 48-72 hours post-delivery
- Preferred over: Topiramate (teratogenic), valproate (contraindicated), CGRP mAbs (insufficient data, long washout)
- Alternative: Metoprolol also reasonable; some prefer it due to beta-1 selectivity
Migraine Prevention in Pregnancy: Where Beta-Blockers Fit
- First-line options: Propranolol or metoprolol (if preventive therapy truly needed)
- Avoid: Topiramate (cleft palate risk), valproate (neural tube defects, contraindicated), CGRP therapies (insufficient data)
- Consider: Magnesium supplementation, riboflavin, non-pharmacologic approaches
- Discontinuation: If migraine improves in pregnancy (common in 2nd-3rd trimester), consider tapering off
Athletes and Active Patients
Exercise intolerance is often the limiting factor for beta-blockers in young, active patients:
- Mechanism: Beta-blockade limits heart rate response to exercise, reducing maximal exercise capacity by 5-15%
- Impact: May be unacceptable for competitive athletes; less significant for recreational exercisers
- Strategies:
- Use lowest effective dose
- Try beta-1 selective agents (metoprolol, atenolol) — may have less exercise impact
- Consider dosing timing: Take medication at bedtime so peak effect is not during exercise
- If unacceptable, switch to a non-beta-blocker preventive
- Note: Beta-blockers are banned in some competitive sports (archery, shooting) due to anti-tremor effects
Elderly Patients
- Start at lower doses (propranolol 20 mg BID, metoprolol 25 mg daily)
- Monitor closely for bradycardia, hypotension, and falls
- Check for interactions with other cardiovascular medications
- May be good choice if comorbid hypertension or atrial fibrillation (rate control)
Menstrual Migraine: Mini-Prophylaxis
For pure menstrual migraine or menstrually-related migraine, short-term (perimenstrual) prophylaxis can be effective:
Beta-Blocker Mini-Prophylaxis Protocol
- Indication: Predictable menstrual migraine in women with regular cycles
- Propranolol: 40-80 mg BID (or propranolol LA 80-160 mg once daily)
- Timing: Start 2-3 days before expected menses, continue through day 3-5 of menstruation
- Duration: ~5-7 days per cycle
- Advantage: Avoids daily medication; targets the vulnerable window
- Alternative agents for mini-prophylaxis: Frovatriptan 2.5 mg BID, naratriptan 1 mg BID, or naproxen 500 mg BID are also effective
Side Effects
| Side Effect | Frequency | Management |
|---|---|---|
| Fatigue / exercise intolerance | Common (10-15%) | Most common reason for discontinuation; try beta-1 selective agent or lower dose |
| Dizziness / hypotension | Common | Reduce dose; ensure adequate hydration |
| Weight gain | Modest (1-2 kg) | Less than with valproate or amitriptyline |
| Depression / mood changes | Lower than previously thought | Recent meta-analyses suggest risk is overstated. Monitor, but don’t avoid solely for depression history. |
| Sleep disturbance / vivid dreams | More with lipophilic agents (propranolol) | Switch to atenolol or nadolol (less CNS penetration) |
| Sexual dysfunction | Uncommon | Switch agent or reduce dose |
| Bronchospasm | Risk with non-selective agents | Avoid propranolol/timolol in asthma; metoprolol or atenolol safer (still cautious) |
| Cold extremities | Common with non-selective | Switch to beta-1 selective agent |
Depression and Beta-Blockers: Updated Perspective
- Historical concern: Beta-blockers were long thought to cause or worsen depression
- Recent evidence: Large meta-analyses (including 2021 Cochrane review of hypertension trials) found no significant increase in depression risk
- Clinical approach: Beta-blockers are no longer contraindicated solely due to depression history. Monitor mood, but don’t reflexively avoid in patients with well-controlled depression.
- Exception: Use caution in patients with active, severe, or treatment-resistant depression
Best Candidates and Contraindications
| Ideal Candidate | Contraindication / Caution |
|---|---|
| Comorbid hypertension | Asthma (non-selective agents absolutely CI; beta-1 selective agents relative CI) |
| Anxiety / performance anxiety | Bradycardia (HR <50) or AV block (2nd/3rd degree) |
| Essential tremor | Decompensated heart failure |
| Tachycardia / palpitations | Severe, active depression (caution, not absolute CI) |
| Pregnancy (when preventive needed) | Diabetes (masks hypoglycemia symptoms, especially non-selective) |
| Cost-sensitive patients | Raynaud phenomenon / severe peripheral vascular disease |
| Migraine with aura (may reduce aura frequency) | Competitive athletes (exercise intolerance) |
| Insurance requires oral preventive trial | Cocaine or amphetamine use (unopposed alpha stimulation risk) |
References
- Silberstein SD, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Report of the Quality Standards Subcommittee of the AAN and the AHS. Neurology. 2012;78(17):1337-1345.
- Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2004;(2):CD003225.
- Diener HC, et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251(8):943-950.
- Steiner TJ, et al. Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging follow-up. Headache. 1988;28(1):15-23.
- Jackson JL, et al. Beta-blockers for the prevention of headache in adults: a systematic review and meta-analysis. PLoS One. 2015;10(3):e0120972.
- Reuter U, et al. Erenumab versus topiramate for prevention of migraine (HER-MES). Lancet Neurol. 2022;21(4):341-351.
- Redelmeier DA, et al. β-Blockers and the risk of depression: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(2):e2034247.
- MacGregor EA. Menstrual migraine: therapeutic approaches. Ther Adv Neurol Disord. 2009;2(5):327-336.
- Amundsen S, et al. Pharmacological treatment of migraine during pregnancy and breastfeeding. Nat Rev Neurol. 2015;11(4):209-219.